How many institutions held BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 in Q2 2021?

108 institutional investors reported BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 for Q2 2021. Use the holders table for investor-level position and value details.

BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI)

Q: What does CUSIP 09075P105 represent in this 13F holders report?

CUSIP 09075P105 is the security identifier for BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 used to aggregate holder disclosures.

CUSIP: 09075P105

Q2 2021 13F Holders as of 30 Jun 2021

Type / Class: Equity / Common Stock, par value $0.001
Shares outstanding: 26,011,000
Total 13F shares: 13,030,148
Share change: +1,964,306
Total reported value: $378,637,038
Put/Call ratio: 163%
Price per share: $29.06
Number of holders: 108
Value change: +$41,282,735
Number of buys: 59
Number of sells: 62

Quarterly Holders Quick Answers

What is CUSIP 09075P105?
CUSIP 09075P105 identifies BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2021
Previous quarter: Q1 2021

Recent filing periods for CUSIP 09075P105:

Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024

Top shareholders of BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
BioXcel Holdings, Inc.	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	25 Jun 2021	3/4/5
BioXcel LLC	3/4/5	10%+ Owner	— class O/S missing	8,546,750	$187,088,358	—	25 Jun 2021	3/4/5
FMR LLC	13F	Company	8.6%	2,229,843	$96,241,000	—	31 Mar 2021	13F
STATE STREET CORP	13F	Company	4.9%	1,275,906	$55,068,000	—	31 Mar 2021	13F
BlackRock Finance, Inc.	13F	Company	4.1%	1,054,104	$45,495,000	—	31 Mar 2021	13F
Artemis Investment Management LLP	13F	Company	4%	1,031,864	$44,397,000	—	31 Mar 2021	13F
ALLIANCEBERNSTEIN L.P.	13F	Company	3.1%	815,881	$35,213,000	—	31 Mar 2021	13F
VANGUARD GROUP INC	13F	Company	3%	789,439	$34,071,000	—	31 Mar 2021	13F
Logos Global Management LP	13F	Company	1.5%	400,000	$17,264,000	—	31 Mar 2021	13F
First Light Asset Management, LLC	13F	Company	1.4%	358,439	$15,470,000	—	31 Mar 2021	13F
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	13F	Company	1.1%	288,605	$12,456,000	—	31 Mar 2021	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.97%	252,640	$10,903,000	—	31 Mar 2021	13F
UBS Group AG	13F	Company	0.76%	197,369	$8,519,000	—	31 Mar 2021	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.73%	190,286	$8,213,000	—	31 Mar 2021	13F
NORTHERN TRUST CORP	13F	Company	0.64%	165,996	$7,165,000	—	31 Mar 2021	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	0.57%	149,326	$6,445,000	—	31 Mar 2021	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.49%	126,465	$5,458,000	—	31 Mar 2021	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.37%	96,021	$4,145,000	—	31 Mar 2021	13F
Lisanti Capital Growth, LLC	13F	Company	0.36%	93,030	$4,015,000	—	31 Mar 2021	13F
CITIGROUP INC	13F	Company	0.34%	87,142	$3,761,000	—	31 Mar 2021	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.32%	82,290	$3,551,000	—	31 Mar 2021	13F
TWO SIGMA ADVISERS, LP	13F	Company	0.31%	80,100	$3,457,000	—	31 Mar 2021	13F
Rafferty Asset Management, LLC	13F	Company	0.27%	70,924	$3,061,000	—	31 Mar 2021	13F
CITADEL ADVISORS LLC	13F	Company	0.27%	70,789	$3,055,000	—	31 Mar 2021	13F
Bank of New York Mellon Corp	13F	Company	0.23%	60,484	$2,609,000	—	31 Mar 2021	13F
Nuveen Asset Management, LLC	13F	Company	0.21%	53,494	$2,309,000	—	31 Mar 2021	13F
ALPS ADVISORS INC	13F	Company	0.17%	44,080	$1,902,000	—	31 Mar 2021	13F
KENNEDY CAPITAL MANAGEMENT LLC	13F	Company	0.16%	41,373	$1,786,000	—	31 Mar 2021	13F
Caption Management, LLC	13F	Company	0.15%	40,000	$1,726,000	—	31 Mar 2021	13F
CSS LLC/IL	13F	Company	0.14%	36,596	$1,579,000	—	31 Mar 2021	13F
APIS CAPITAL ADVISORS, LLC	13F	Company	0.14%	36,000	$1,554,000	—	31 Mar 2021	13F
Swiss National Bank	13F	Company	0.13%	33,400	$1,442,000	—	31 Mar 2021	13F
JANE STREET GROUP, LLC	13F	Company	0.11%	28,447	$1,228,000	—	31 Mar 2021	13F
AlphaCentric Advisors LLC	13F	Company	0.1%	25,000	$1,079,000	—	31 Mar 2021	13F
MORGAN STANLEY	13F	Company	0.09%	24,265	$1,047,000	—	31 Mar 2021	13F
DAVENPORT & Co LLC	13F	Company	0.09%	24,150	$1,042,000	—	31 Mar 2021	13F
DEUTSCHE BANK AG\	13F	Company	0.09%	23,835	$1,029,000	—	31 Mar 2021	13F
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM	13F	Company	0.09%	23,800	$1,027,000	—	31 Mar 2021	13F
Weiss Multi-Strategy Advisers LLC	13F	Company	0.08%	22,104	$954,000	—	31 Mar 2021	13F
NEW YORK STATE COMMON RETIREMENT FUND	13F	Company	0.08%	22,070	$953,000	—	31 Mar 2021	13F
THRIVENT FINANCIAL FOR LUTHERANS	13F	Company	0.08%	20,703	$893,000	—	31 Mar 2021	13F
MOODY ALDRICH PARTNERS LLC	13F	Company	0.08%	20,247	$874,000	—	31 Mar 2021	13F
Knoll Capital Management, LLC	13F	Company	0.08%	20,000	$863,000	—	31 Mar 2021	13F
Russell Investments Group, Ltd.	13F	Company	0.08%	20,025	$862,000	—	31 Mar 2021	13F
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	13F	Company	0.07%	19,271	$832,000	—	31 Mar 2021	13F
GROUP ONE TRADING LLC	13F	Company	0.07%	17,876	$772,000	—	31 Mar 2021	13F
Allianz Asset Management GmbH	13F	Company	0.07%	17,797	$768,000	—	31 Mar 2021	13F
PANAGORA ASSET MANAGEMENT INC	13F	Company	0.07%	17,259	$745,000	—	31 Mar 2021	13F
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC	13F	Company	0.06%	16,600	$716,456	—	31 Mar 2021	13F
Capital Investment Advisory Services, LLC	13F	Company	0.06%	16,600	$716,000	—	31 Mar 2021	13F

Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI) as of Q2 2021

As of 30 Jun 2021, BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI) was held by 108 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 13,030,148 shares. The largest 10 holders included FMR LLC, STATE STREET CORP, Artemis Investment Management LLP, BlackRock Inc., ALLIANCEBERNSTEIN L.P., VANGUARD GROUP INC, MASSACHUSETTS FINANCIAL SERVICES CO /MA/, GEODE CAPITAL MANAGEMENT, LLC, Altshuler Shaham Ltd, and CAAS CAPITAL MANAGEMENT LP. This page lists 108 institutional shareholders reporting positions in this security for the Q2 2021 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2021 vs Q1 2021 Across Filers

Q1 2021 holders

114

Q2 2021 holders

108

Holder diff

-6

Investor	Q1 2021 Shares	Q2 2021 Shares	Share Diff	Share Chg %	Q1 2021 Value $	Q2 2021 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.